8-K: Abpro and Celltrion Unveil Promising Preclinical Data for Cancer Therapy ABP-102/CT-P72 at AACR 2025

Abpro and Celltrion presented preclinical data at AACR 2025 for ABP-102/CT-P72, a potential best-in-class HER2 x CD3 T-cell engager, showing superior tumor selectivity, potent efficacy, and an improved safety profile.

Summary

• Abpro Holdings, Inc. and Celltrion announced preclinical data for ABP-102/CT-P72 at the American Association for Cancer Research (AACR) Annual Meeting 2025.
• ABP-102/CT-P72 is a tetravalent bispecific HER2 x CD3 T-cell engager designed to selectively target HER2-overexpressing tumors.
• Preclinical findings suggest that ABP-102/CT-P72 has the potential to surpass existing HER2-targeted therapies in both efficacy and safety.
• The data indicates that ABP-102/CT-P72 achieves potent cytotoxicity in HER2-overexpressing breast and gastric cancer models while reducing activity against HER2-low cells.
• In vivo studies showed ABP-102/CT-P72 had up to a two-fold increase in tumor suppression compared to a biosimilar of runimotamab.
• Dose escalation studies in cynomolgus monkeys confirmed that ABP-102/CT-P72 was well tolerated, even at doses exceeding 180 times the maximum tolerated dose observed with the parental antibody.
• Clinical trials for ABP-102/CT-P72 are planned to start in the first half of 2026.

Sentiment

Score: 8

Explanation: The document presents positive preclinical data for a potential cancer therapy, highlighting improved efficacy and safety compared to existing treatments. The planned clinical trials further contribute to a positive outlook.

Positives

• ABP-102/CT-P72 demonstrates highly selective tumor killing, achieving potent cytotoxicity in HER2-overexpressing cancer models while reducing activity against HER2-low cells.
• The therapy shows enhanced tumor growth inhibition, with in vivo studies indicating up to a two-fold increase in tumor suppression compared to a biosimilar of runimotamab.
• ABP-102/CT-P72 is engineered for functionally monovalent CD3 binding, minimizing cytokine-related toxicities.
• The therapy exhibits improved tolerability, as confirmed by dose escalation studies in cynomolgus monkeys, suggesting a broader therapeutic window.

Risks

• The forward-looking statements are subject to risks and uncertainties that may cause actual events or results to differ materially from those expressed or implied.
• These risks include the timing and advancement of development programs, the ability to obtain regulatory approval, and the ability to maintain intellectual property.

Future Outlook

Clinical trials for ABP-102/CT-P72 are planned to start in the first half of 2026, paving the way for a broader therapeutic window in clinical trials.

Management Comments

• Robert J. Markelewicz, Jr., MD, MMSc, Chief Medical Officer of Abpro, stated that the preclinical data positions ABP-102/CT-P72 as a potential best-in-class HER2-targeting bispecific T-cell engager.
• Soo Young Lee, Senior Vice President and Head of the New Drug Division at Celltrion Inc., added that ABP-102/CT-P72 represents a breakthrough in the bispecific antibody space, addressing long-standing toxicity barriers.

Industry Context

The development of ABP-102/CT-P72 addresses the need for safer and more effective HER2-targeted therapies, as HER2-positive cancers represent a significant portion of breast, gastric, pancreatic, colorectal, and other cancer cases. The potential for reduced toxicity and improved efficacy compared to existing therapies positions ABP-102/CT-P72 as a competitive candidate in the bispecific antibody space.

Comparison to Industry Standards

• The document mentions runimotamab, a benchmark HER2 x CD3 bispecific antibody, as a comparator.
• ABP-102/CT-P72 demonstrated up to a two-fold increase in tumor suppression compared to a biosimilar of runimotamab in in vivo studies.
• The improved tolerability profile of ABP-102/CT-P72 in cynomolgus monkeys, with doses exceeding 180 times the maximum tolerated dose of the parental antibody, suggests a significant advantage over previous HER2-targeting T-cell engagers.

Stakeholder Impact

• Positive preclinical results could lead to improved treatment options for patients with HER2-positive cancers.
• Successful clinical trials and commercialization of ABP-102/CT-P72 could benefit shareholders through increased company value.
• The collaboration between Abpro and Celltrion could strengthen their positions in the biopharmaceutical industry.

Next Steps

• Clinical trials for ABP-102/CT-P72 are planned to start in the first half of 2026.

Key Dates

Keywords

ABP-102/CT-P72, HER2 x CD3 T-cell engager, Celltrion, Abpro, Cancer therapy, Preclinical data, AACR 2025, Bispecific antibody, Tumor selectivity, Cytotoxicity, HER2-positive cancers